Moberg Pharma AB interim report January - March 2019
DIVESTED OTC BUSINESS - TIME FOR MOBERG PHARMA 2.0FIRST QUARTER (JAN-MAR 2019) · Net profit after tax SEK 563.9 million (2.0) · Total profit for the period SEK 504.5 million (5.6) · Diluted earnings per share SEK 31.95 (0.12) · Net revenue SEK 15.6 million (0.0) * · EBITDA SEK 7.3 million (-10.0) * · Operating profit (EBIT) SEK 5.0 million (-10.0) * · Operating cash flow per share SEK 1.45 (0.66) · Cash and cash equivalents amounted to SEK 1 596.9 million (102.5) * represents continuing operations only SIGNIFICANT EVENTS IN THE FIRST QUARTER · On